Jacob Gottlieb is the manager and founder of Visium Asset Management. The fund was formed back in 2005 in New York, and since then it has raised its assets under management to over $7 billion. Visium Asset Management is equipped with a variety of strategies which helped it make 15% in average annualized returns under different market conditions. As of March 31, the largest amounts of money in the 13F equity portfolio of the fund were allocated towards the healthcare sector with 36.15% of its public equity portfolio in those stocks. This is not surprising, given that Jacob Gottlieb holds a medical degree, which he successfully uses for making long and short bets in healthcare, using fundamental and event-driven analysis. The results of our research, based on a series of backtests we conducted for the period from 2007 to 2012, show that the top-five large-cap picks of Gottlieb have managed to deliver 1.13% average monthly returns, versus 0.22% returns for the S&P 500. At the same time, the average generated alpha for his fund equaled out to 0.40% per month. Therefore, let’s take a quick look at the top three large-cap positions of Gottlieb, in Allergan PLC (NYSE:AGN), Perrigo Company (NYSE:PRGO) and CIGNA Corporation (NYSE:CI).
We don’t just track the latest moves of funds and stocks at Insider Monkey. We are, in fact, more interested in their 13F filings, which we use to determine the top 15 small-cap stocks held by the funds we track. We gather and share this information based on 16 years of research, with backtests for the period between 1999 and 2012 and forward testing for the last 2.5 years. The results of our analysis show that these 15 most popular small-cap picks have a great potential to outperform the market, beating the S&P 500 Total Return Index by nearly one percentage point per month in backtests. Moreover, since the beginning of forward testing in August 2012, the strategy worked brilliantly, outperforming the market every year and returning 135%, which is more than 80 percentage points higher than the returns of the S&P 500 ETF (SPY) (see more details).
Following a 101% increase in the ownership of Allergan PLC (NYSE:AGN) during the first three months of the year, Visium Asset Management held 1.46 million shares valued at $435.24 million. On June 4, Bank of America Merrill Lynch reported an increase in the target price of this pharmaceutical giant, lifting it to $350 per share. The analysts believe that the stock still has 14-15% upside, as the growth potential has not been fully priced-in yet. According to our extensive database, which covers over 700 hedge fund managers, Viking Global, managed by Andreas Halvorsen, holds the largest position in Allergan PLC (NYSE:AGN) with 6.11 million shares valued at $1.82 billion. The second-largest stake is held by Paulson & Co, led by John Paulson, which owns some 5.64 million shares worth $1.68 billion.